North Bethesda, MD, United States of America

Paul A Moore

USPTO Granted Patents = 79 (Patent Applications = 23)

CIPO Patents = 8 (Patent Applications = 8)

EPO Patents = 14 (Patent Applications = 12)

Average Co-Inventor Count = 4.8

ph-index = 15

Forward Citations = 674(Granted Patents)

Inventors with similar research interests:

Location History:

Dallas, TX (US) (1977)
Tampa, FL (US) (1982)
Aberdeen, GB (2003)
Germantown, MD (US) (1997 - 2008)
Bethesda, MD (US) (2012 - 2020)
North Bethesda, MD (US) (2004 - 2023)
North Potomac, MD (US) (2018 - 2024)
Rockville, MD (US) (2023 - 2024)

Company Filing History:

38 out of 676

Human Genome Sciences, Inc.

5. 3 out of 832,680

Other

patents

Years Active: 1977-2025

Loading Chart...

79 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435155 - CD137 binding molecules and uses thereof (2025-10-07),

2. 11942149 - Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof (2024-03-26),

3. 11858991 - LAG-3-binding molecules and methods of use thereof (2024-01-02),

4. 11840571 - Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 (2023-12-12),

5. 11820818 - Multi-chain polypeptide-containing tri-specific binding molecules (2023-11-21),

6. 11802164 - Methods and compositions for diagnosing and treating diseases (2023-10-31),

7. 11697684 - Tri-specific binding molecules that specifically bind to multiple cancer antigens (2023-07-11),

8. 11685781 - Variant CD3-binding domains and their use in combination therapies for the treatment of disease (2023-06-27),

9. 11639386 - Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof (2023-05-02),

10. 11623959 - PD-1-binding molecules and methods of use thereof (2023-04-11),

11. 11459394 - Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof (2022-10-04),

12. 11384149 - Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof (2022-07-12),

13. 11098119 - Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof (2021-08-24),

14. 11072653 - LAG-3-binding molecules and methods of use thereof (2021-07-27),

15. 10954301 - Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof (2021-03-23),

Title: The Innovative Journey of Paul A Moore

Introduction: Paul A Moore, a talented inventor hailing from North Bethesda, MD, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Paul A Moore's latest patents include a revolutionary smart home device that integrates artificial intelligence for enhanced security and convenience, as well as a cutting-edge medical device designed to improve patient outcomes in the healthcare industry.

Career Highlights: With a career spanning over two decades, Paul A Moore has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing innovative solutions. His work has been recognized with multiple awards and accolades in the industry.

Collaborations: Throughout his career, Paul A Moore has collaborated with leading technology companies, research institutions, and universities to bring his inventions to life. His ability to work effectively in multidisciplinary teams has led to the successful commercialization of several groundbreaking products.

Conclusion: In conclusion, Paul A Moore's passion for innovation and dedication to pushing the boundaries of technology have solidified his reputation as a respected inventor in the industry. His relentless pursuit of excellence continues to inspire future generations of inventors to think outside the box and create solutions that have a lasting impact on society.

This text is generated by artificial intelligence and may not be accurate.